The Norwegian research programme for Global Health and Vaccination Research (GLOBVAC) has on behalf of the Norwegian Ministry of Foreign Affairs contributed financially to an international trial for EBOLA-vaccine. Evaluation of Ebola vaccines in Guineawill be conducted by the World Health Organisation, Doctors Without Borders, the Norwegian Institute of Public Health and others.Given the exceptional nature of the spread of Ebola in West Africa, The Norwegian Ministry of Foreign Affairs and The Norwegian Agency for Development Cooperation (Norad) asked the Research Council of Norway (RCN) to conduct a speedy decision concerning financing this project. The project has its origin from a broad workgroup which has assessed alternative strategies for vaccine trials in Guinea. The RCN will contribute with approximately 3 million dollars to the study.
The project will start already in December 2014, and will assess efficacy, effectiveness and safety of an EBOLA-vaccine. The researchers will perform clinical trials on groups with high risk of transmission, for instance fieldworkers and health personnel. In addition the vaccine will be evaluated in the context of ring vaccination of the population in communities where the Ebola-virus is active.